AI Verdict
REGN has stronger fundamentals based on our AI analysis.
REGN vs ZTS Fundamental Comparison
| Metric | REGN | ZTS |
|---|---|---|
| Revenue | $14.3B | $9.5B |
| Net Income | $4.5B | $2.7B |
| Net Margin | 31.4% | 28.2% |
| ROE | 14.4% | 80.2% |
| ROA | 11.1% | 17.3% |
| Current Ratio | 4.13x | 3.03x |
| Debt/Equity | 0.06x | 2.71x |
| EPS | $41.48 | $6.02 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
REGN vs ZTS: Frequently Asked Questions
Is REGN or ZTS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. REGN is rated BUY (80% confidence) while ZTS is rated BUY (78% confidence). This is not investment advice.
How does REGN compare to ZTS fundamentally?
REGENERON PHARMACEUTICALS, INC. has ROE of 14.4% vs Zoetis Inc.'s 80.2%. Net margins are 31.4% vs 28.2% respectively.
Which stock pays higher dividends, REGN or ZTS?
REGN has a dividend yield of N/A or no dividend while ZTS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in REGN or ZTS for long term?
For long-term investing, consider that REGN has BUY rating with 80% confidence, while ZTS has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about REGN vs ZTS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For REGN vs ZTS, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.